JPWO2021030554A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021030554A5
JPWO2021030554A5 JP2022508828A JP2022508828A JPWO2021030554A5 JP WO2021030554 A5 JPWO2021030554 A5 JP WO2021030554A5 JP 2022508828 A JP2022508828 A JP 2022508828A JP 2022508828 A JP2022508828 A JP 2022508828A JP WO2021030554 A5 JPWO2021030554 A5 JP WO2021030554A5
Authority
JP
Japan
Prior art keywords
compound
salt
formula
haloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544769A (ja
JP7635206B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046116 external-priority patent/WO2021030554A1/en
Publication of JP2022544769A publication Critical patent/JP2022544769A/ja
Publication of JPWO2021030554A5 publication Critical patent/JPWO2021030554A5/ja
Application granted granted Critical
Publication of JP7635206B2 publication Critical patent/JP7635206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508828A 2019-08-14 2020-08-13 Cftrモジュレータの作製プロセス Active JP7635206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886660P 2019-08-14 2019-08-14
US62/886,660 2019-08-14
PCT/US2020/046116 WO2021030554A1 (en) 2019-08-14 2020-08-13 Process of making cftr modulators

Publications (3)

Publication Number Publication Date
JP2022544769A JP2022544769A (ja) 2022-10-21
JPWO2021030554A5 true JPWO2021030554A5 (enrdf_load_stackoverflow) 2023-07-05
JP7635206B2 JP7635206B2 (ja) 2025-02-25

Family

ID=72243221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508828A Active JP7635206B2 (ja) 2019-08-14 2020-08-13 Cftrモジュレータの作製プロセス

Country Status (22)

Country Link
US (2) US11584761B2 (enrdf_load_stackoverflow)
EP (1) EP4013741B1 (enrdf_load_stackoverflow)
JP (1) JP7635206B2 (enrdf_load_stackoverflow)
KR (1) KR20220064365A (enrdf_load_stackoverflow)
CN (1) CN114555556B (enrdf_load_stackoverflow)
AR (1) AR119770A1 (enrdf_load_stackoverflow)
AU (1) AU2020330570B2 (enrdf_load_stackoverflow)
BR (1) BR112022002604A2 (enrdf_load_stackoverflow)
CA (1) CA3150736A1 (enrdf_load_stackoverflow)
CO (1) CO2022002637A2 (enrdf_load_stackoverflow)
ES (1) ES2984127T3 (enrdf_load_stackoverflow)
HR (1) HRP20240606T1 (enrdf_load_stackoverflow)
HU (1) HUE066896T2 (enrdf_load_stackoverflow)
IL (2) IL290574B2 (enrdf_load_stackoverflow)
LT (1) LT4013741T (enrdf_load_stackoverflow)
MX (1) MX2022001829A (enrdf_load_stackoverflow)
PL (1) PL4013741T3 (enrdf_load_stackoverflow)
SI (1) SI4013741T1 (enrdf_load_stackoverflow)
TW (1) TW202120517A (enrdf_load_stackoverflow)
UY (1) UY38837A (enrdf_load_stackoverflow)
WO (1) WO2021030554A1 (enrdf_load_stackoverflow)
ZA (1) ZA202201793B (enrdf_load_stackoverflow)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782408B2 (en) 2014-10-06 2017-10-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
MX2020008268A (es) 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20220313698A1 (en) * 2019-08-14 2022-10-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2022001828A (es) 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
CN119095597A (zh) 2022-02-03 2024-12-06 弗特克斯药品有限公司 治疗囊性纤维化的方法
US20250122218A1 (en) 2022-02-08 2025-04-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JP2025517322A (ja) 2022-05-16 2025-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
CN116041169A (zh) * 2022-07-29 2023-05-02 北京先通国际医药科技股份有限公司 一种合成修饰脂肪酸型pet试剂前体关键中间体的工艺路线及其用途
WO2025166342A1 (en) 2024-02-04 2025-08-07 Vertex Pharmaceuticals Incorporated Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis
WO2025171098A1 (en) 2024-02-07 2025-08-14 Vertex Pharmaceuticals Incorporated Compositions for the treatment of cftr-mediated diseases

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2677682A (en) 1951-08-24 1954-05-04 American Cyanamid Co Sulfonamido pteridines
ID18983A (id) 1996-12-04 1998-05-28 Lilly Co Eli Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US7332612B2 (en) 2001-11-14 2008-02-19 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of losartan potassium and process for their preparation
ZA200604578B (en) 2003-11-14 2008-05-28 Vertex Pharma Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters
ES2631362T3 (es) 2004-01-30 2017-08-30 Vertex Pharmaceuticals Incorporated Moduladores de transportadores de casete de unión a ATP
BRPI0511321B8 (pt) 2004-06-24 2021-05-25 Vertex Pharma moduladores de transportadores de cassete de ligação de atp, composição farmacêutica e seus usos
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
AU2006279810B2 (en) 2005-08-11 2011-10-27 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2007053641A2 (en) 2005-11-01 2007-05-10 Mars, Incorporated A-type procyanidins and inflammation
EP1974212A1 (en) 2005-12-27 2008-10-01 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
NZ569327A (en) 2005-12-28 2011-09-30 Vertex Pharma 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
HUE027630T2 (en) 2006-04-07 2016-10-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US7553855B2 (en) 2006-05-12 2009-06-30 Vertex Pharmaceuticals Incorporated Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101715450B (zh) 2006-11-03 2013-03-13 沃泰克斯药物股份有限公司 作为cftr调控剂的氮杂吲哚衍生物
BRPI0811065A2 (pt) 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
NZ583848A (en) 2007-09-14 2012-07-27 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PL2639222T3 (pl) 2007-12-07 2017-02-28 Vertex Pharmaceuticals Incorporated Sposób wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
CN103626744B (zh) 2007-12-07 2016-05-11 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
EP2271622B1 (en) 2008-02-28 2017-10-04 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR Modulators
MX366161B (es) 2008-08-13 2019-07-01 Vertex Pharmaceutical Incorporated Composicion farmaceutica y su administracion.
WO2010048526A2 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals, Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR101559963B1 (ko) 2008-11-06 2015-10-26 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송자의 조절자
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
CA2938650C (en) 2009-09-04 2018-01-09 Raptor Pharmaceuticals Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
CA2792207A1 (en) 2010-03-19 2011-09-22 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE052759T2 (hu) 2010-03-25 2021-05-28 Vertex Pharma (R)-1(2,2-difluorbenzo(D)(1,3)dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi-2- metilpropán-2-il)-1H-indol-5-il)-ciklo-propánkarboxamid amorf formájának szilárd diszperziója
EP4005559B1 (en) 2010-04-07 2025-02-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
HRP20160682T1 (hr) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
WO2011133951A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド (r)−1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)−n−(1−(2,3−ジヒドロキシプロピル)−6−フルオロ−2−(1−ヒドロキシ−2−メチルプロパン−2−イル)−1h−インドール−5−イル)シクロプロパンカルボキサミドを含む医薬組成物およびその投与
WO2012027731A2 (en) 2010-08-27 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2012093773A2 (ko) 2011-01-04 2012-07-12 에이큐 주식회사 광고 정보 제공 시스템
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP6063455B2 (ja) 2011-05-18 2017-01-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたイバカフトルの誘導体
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RS59262B1 (sr) 2012-01-25 2019-10-31 Vertex Pharma Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
WO2013130669A1 (en) 2012-02-27 2013-09-06 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
AU2012377446A1 (en) 2012-04-20 2014-10-23 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SG10201913581UA (en) 2012-11-02 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
WO2015051043A1 (en) 2013-10-01 2015-04-09 Amgen Inc. Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
CN105848657B (zh) 2013-11-12 2020-05-22 沃泰克斯药物股份有限公司 制备用于治疗cftr介导的疾病的药物组合物的方法
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
US9782408B2 (en) 2014-10-06 2017-10-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
RS62259B1 (sr) 2014-11-18 2021-09-30 Vertex Pharma Proces izvođenja ispitivanja visoke propusnosti tečne hromatografije visokih performansi
WO2016121399A1 (ja) 2015-01-29 2016-08-04 京セラ株式会社 測定装置およびセンサシステム
AU2016243171B2 (en) 2015-03-31 2020-10-08 Concert Pharmaceuticals, Inc. Deuterated VX-661
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
MA42954A (fr) 2015-09-25 2018-08-01 Vertex Pharmaceuticals Europe Ltd Potentialisateurs cftr deutérés
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA3019663A1 (en) 2016-04-07 2017-10-12 Proteostasis Therapeutics, Inc. Ivacaftor analogues containing silicone atoms
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
WO2017223188A1 (en) 2016-06-21 2017-12-28 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US20180012171A1 (en) 2016-07-05 2018-01-11 Elie Massabki On-demand resource allocation
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
AU2017336156B2 (en) 2016-09-30 2021-10-21 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
AU2017348186A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating CFTR
US20190256474A1 (en) 2016-10-26 2019-08-22 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
AU2017348183A1 (en) 2016-10-26 2019-05-16 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating CFTR
CA3041819A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
NZ754085A (en) 2016-11-18 2025-05-02 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CA3046968A1 (en) 2016-12-16 2018-06-21 Joseph Walter Strohbach Bicyclic heteroaryl derivatives as cftr potentiators
US20200123137A1 (en) 2016-12-20 2020-04-23 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations
KR20190135029A (ko) 2017-03-30 2019-12-05 에프. 호프만-라 로슈 아게 Hpk1의 억제제인 이소퀴놀린
MA49061A (fr) 2017-04-28 2021-04-21 Proteostasis Therapeutics Inc Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20210069174A1 (en) 2017-07-01 2021-03-11 Vertex Pharmaceuticals Incorporated Compositions and methods for treatment of cystic fibrosis
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
CA3069225A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
EP3691638B1 (en) 2017-10-06 2024-12-11 Proteostasis Therapeutics, Inc. Compounds, compositions and methods for increasing cftr activity
EP3697774A1 (en) 2017-10-19 2020-08-26 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
EP4484402A3 (en) 2017-12-01 2025-07-02 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019113089A1 (en) 2017-12-04 2019-06-13 Vertex Pharmaceuticals Incorporated Compositions for treating cystic fibrosis
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MX2020008268A (es) 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
WO2019191620A1 (en) 2018-03-30 2019-10-03 Vertex Pharmaceuticals Incorporated Crystalline forms of modulators of cftr
US20210139514A1 (en) 2018-04-05 2021-05-13 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) * 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP4218754A3 (en) 2018-11-14 2023-08-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2020128925A1 (en) 2018-12-21 2020-06-25 Novartis Ag Macrocyclic compounds and their use in the treatment of disease
EP3921313A1 (en) 2019-02-06 2021-12-15 Novartis AG N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2020191227A1 (en) 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
AR118555A1 (es) 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en) 2019-04-17 2020-10-22 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cftr
WO2020242935A1 (en) 2019-05-29 2020-12-03 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US20220313698A1 (en) 2019-08-14 2022-10-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
MX2022001828A (es) 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
AU2020382827A1 (en) 2019-11-12 2022-05-26 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity
JP7721517B2 (ja) 2019-11-12 2025-08-12 ジェンザイム・コーポレーション Cftr活性の欠損が介在する状態を治療するための5員ヘテロアリールアミノスルホンアミド
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
KR20230051216A (ko) 2020-08-13 2023-04-17 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
EP4225761A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20240150377A1 (en) 2020-10-07 2024-05-09 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20230382925A1 (en) 2020-10-07 2023-11-30 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN116670143A (zh) 2020-10-07 2023-08-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控因子的调节剂
EP4225763A1 (en) 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법

Similar Documents

Publication Publication Date Title
JPWO2021030554A5 (enrdf_load_stackoverflow)
JP2024105360A5 (enrdf_load_stackoverflow)
JP2010510976A5 (enrdf_load_stackoverflow)
JP2012532135A5 (enrdf_load_stackoverflow)
JP2008505932A5 (enrdf_load_stackoverflow)
JP2003519207A5 (enrdf_load_stackoverflow)
CN1110682A (zh) 杂环化合物的亚磺酰化方法
JP2007284431A5 (ja) 芳香族アミン化合物
JP2004505965A5 (enrdf_load_stackoverflow)
JP2006523241A5 (enrdf_load_stackoverflow)
JP2020012007A5 (enrdf_load_stackoverflow)
JPS6176479A (ja) 4,4‐ジ置換5‐メチレン‐1,3‐ジオキソラン‐2‐オンの製法
JP2007538042A5 (enrdf_load_stackoverflow)
JP2008116785A5 (enrdf_load_stackoverflow)
JP2003313184A5 (enrdf_load_stackoverflow)
JP2021503522A5 (enrdf_load_stackoverflow)
JP2009537607A5 (enrdf_load_stackoverflow)
KR840005449A (ko) 벤조티오 피라노 피리디논
Chatani et al. Preparation of vinylgermanes and a germole by the Pd-catalyzed reactions of Me (in3) GeCn with acetylenes
JPWO2021085535A5 (enrdf_load_stackoverflow)
JP4667575B2 (ja) 1,3−ジアルキルイミダゾリウムヨウ素塩の製造方法
JP2007513070A5 (enrdf_load_stackoverflow)
JP2021006403A5 (enrdf_load_stackoverflow)
JP2004137258A5 (enrdf_load_stackoverflow)
JP2020111728A5 (enrdf_load_stackoverflow)